Monitoring the HIV response for trans people in Europe and Central Asia Authors: S. North, P. A. Calderon‐Cifuentes, D. Raben, S. Bivol, A. Rinder Stengaard, T. Noori Published: 2026 ABSTRACT AbstractObjectivesThis paper aims to present available data on national responses to HIV for trans populations related to national policies, legal environments and prevention programmes, as reported by European and Central Asian countries.MethodsBetween February and April 2024, the European Centre for Disease Prevention and Control disseminated an online questionnaire to nominated National HIV Focal Points in Europe and Central Asia to monitor implementation of the Dublin Declaration on partnership to fight HIV/AIDS. This included questions on national HIV policies, legal environments, prevention programmes, the continuum of HIV care and avoidance of healthcare.ResultsTwenty‐three of 50 countries involve trans people in the content and development of national HIV strategies and policies related to their health. Two of 47 countries enact punitive legislation against trans people, and there is some evidence of healthcare seeking avoidance among trans people due to stigma in healthcare settings. In half of reporting countries (23/46), trans people have free (no cost) access to sexually transmitted infection testing and treatment. Limited availability and quality of national HIV data on the number of trans people diagnosed, treated and virally suppressed prevent the accurate measurement of progress towards global HIV targets for this key population.ConclusionsTrans people are to a lesser extent than other key populations addressed in national HIV policies and strategies, and the data available from countries suggest lower levels of access to services because of costs, unsupportive legal environments and avoidance of seeking healthcare services. Without comprehensive and trans‐inclusive data collection, national and regional HIV responses may risk neglecting the specific needs of trans people in HIV prevention. INTRODUCTION Transgender, or trans, people are individuals whose gender identity differs from the sex assigned at birth, encompassing transgender women, transgender men, non‐binary and other gender‐diverse people. The terms ‘trans’ and ‘transgender’ are western constructs used internationally to describe a heterogeneous group whose local expressions and terminologies vary substantially across geographies and cultures. Trans people are internationally recognized as a key population in the HIV response alongside gay men and other men who have sex with men, people who inject drugs, sex workers, and people in prisons and other closed settings; defined by their disproportionate HIV burden and structural barriers to care [1]. An intersectional framework reveals how trans people who simultaneously navigate marginalized positions across race, migration status, sexual orientation, occupation and neurodivergence face compounding structural exclusion and have a higher risk of acquiring HIV [2]. Trans people, as a population group, are disproportionately affected by HIV globally with estimated prevalences of 19.9% among trans‐feminine individuals and 2.6% among trans‐masculine individuals [3]. In the Global North—encompassing Australia, Europe and North America—trans‐feminine individuals are estimated to be approximately 48 times more likely to acquire HIV than other adults over 15 years of age [3]. HIV prevalence data for trans people are available from nine European and Central Asian (ECA) countries, ranging from <1% in two (Romania and Sweden) to ≥8% also in two countries (Georgia and Italy) [4, 5]. Surveillance data from seven European Union (EU) and European Economic Area (EEA) countries suggest that 0.8% of new HIV diagnoses were among trans people in 2023 [6]. Of these, 86% were trans migrants, primarily from Latin America and the Caribbean, and 29% were diagnosed late (CD4 cell count <350 cells per mm3), considerably fewer than the 52% reported for all new diagnoses in 2023. Trans populations in the EU/EEA have been identified as one of the most underserved populations within HIV prevention, testing and treatment systems [7]. Exclusion from healthcare and employment opportunities, combined with hostile legal environments, continue to marginalize trans people and heighten minority stress levels, which can influence elevated HIV risk behaviours [3]. To reduce inequalities driving the HIV epidemic, the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95‐95‐95 targets [8] also includes targets so that: <10% of countries have punitive laws and policies that restrict access to HIV services and unfairly target people living with, at risk of or affected by HIV; <10% of people living with HIV (PLHIV) and key populations experience stigma and discrimination; and < 10% of women, girls, PLHIV and key populations experience gender inequality and violence [8]. This paper aims to present the available data on national responses to HIV for trans populations related to national policies, legal environments and prevention programmes, as reported by ECA countries within the European Centre for Disease Prevention and Control (ECDC) Dublin Declaration HIV monitoring system. METHODS Since 2009, ECDC has been assessing and reporting on implementation progress of the ‘Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia’ through an annual monitoring process [9]. To monitor progress towards global commitments on HIV/AIDS, ECDC's HIV monitoring questionnaire items are routinely adapted in close alignment with the latest Global AIDS Monitoring (GAM) indicators [10]. Notably, GAM indicators use the terms transgender people, transwomen and transmen; however, this paper will use the terms trans people, trans‐feminine and trans‐masculine, to reflect the inclusion of non‐binary identities within these sub‐populations. It should also be noted that at the time of data collection, 2024 GAM indicator guidance [10] referred to third gender in the context of legal protections for trans people; however, non‐binary is now the internationally recognized terminology [11]. Data sources used by countries reporting within the HIV monitoring tool varied across indicators, but typically included information from national strategies, policies and guidelines or data from surveillance, specific studies, behavioural surveillance surveys and programming. Less frequently, expert opinion was an eligible country data source for some HIV monitoring indicators. The descriptive analyses in this paper are based on Dublin Declaration monitoring data collected by ECDC between February and April 2024 through an online reporting tool disseminated to representatives from ministries of health, public health and civil society in 53 of the ECA 55 countries (53 countries of the WHO European Region, plus Kosovo and Liechtenstein). Representatives from the EU/EEA were nominated by national ECDC focal points. The 2024 questionnaire was not sent to Belarus and Russia. If no new data were reported by a country, the latest available data reported within the last five years (up until 2019) were used. If a country provided information that surpassed the five‐year cut‐off, or did not respond to a question in the current or any previous online reporting rounds, it was counted as a missing response. Descriptive analyses of HIV monitoring data related to trans people focused on national reporting on 2024 GAM indicators [10] concerning trans people related to legal environments, HIV policy, avoidance of seeking healthcare services and Continuum of HIV Care (CoC). Questionnaire items related to the availability and cost of HIV and sexually transmitted infection (STI) prevention programmes asked countries to indicate which key populations are provided free (no cost) condoms and lubricant, as well as provide information on the cost to the individual for STI testing and treatment (available free, free if individual has insurance, available at a cost, not available). A detailed list of 2024 indicators used in the analyses, and weblink to the most recent questionnaire items, can be found in Table S1. Findings are presented as proportions according to the provided questionnaire response options, and where possible comparisons are made with questionnaire data reported for other HIV key populations. RESULTS A total of 50 out of 53 eligible ECA countries provided data on at least one subset of the indicators presented in this paper (no data from Israel, Turkmenistan and Uzbekistan). Legal environment Forty‐seven countries reported to neither criminalize nor prosecute trans people because of their gender identity, and 37 have specific legal protections in place for trans people (Table 1). TABLE 1Number and names of countries with specific legal protections for trans people in Europe and Central Asia, end of 2023 (n = 47). a Type of legal protectionNumber of reporting countriesList of country namesConstitutional prohibition of discrimination based on any grounds33Albania, Andorra, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, b Czechia, Denmark, Estonia, Finland, France, Georgia, Greece, Iceland, Italy, Kosovo, Kyrgyzstan, Liechtenstein, Luxembourg, Moldova, Monaco, Montenegro, Poland, Portugal, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye, Ukraine, United Kingdom.Constitutional prohibition of discrimination based on sex31Albania, Austria, Bulgaria, Croatia, b Czechia, Estonia, Finland, France, Georgia, Germany, Greece, Iceland, Ireland, Italy, Kosovo, Kyrgyzstan, Lithuania, Luxembourg, Malta, Moldova, Monaco, Montenegro, North Macedonia, Poland, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom.Prohibitions of discrimination in employment based on gender diversity32Albania, Austria, Belgium, Bulgaria, Croatia, b Czechia, Estonia, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Kosovo, Kyrgyzstan, Luxembourg, Malta, Moldova, Monaco, Montenegro, the Netherlands, North Macedonia, Norway, b Poland, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland, United Kingdom.Constitutional prohibition of discrimination based on gender diversity23Albania, Austria, Bulgaria, Czechia, Estonia, Finland, France, Georgia, Germany, Greece, Iceland, Italy, Kosovo, Kyrgyzstan, Malta, Moldova, Monaco, Montenegro, Portugal, Spain, Sweden, Switzerland, United Kingdom.Other non‐discrimination provisions specifying gender diversity18Austria, Belgium, Bulgaria, Estonia, Finland, France, Germany, Greece, Iceland, Kosovo, Luxembourg, Monaco, the Netherlands, Norway, b Slovenia, Spain, Sweden, United Kingdom.A third gender c is legally recognized6Austria, Germany, Greece, Iceland, Luxembourg, Malta.No legal protections in place6Azerbaijan, Cyprus, Hungary, b Latvia, Romania, San Marino. Note: Information provided by countries is self‐reported and may not have been verified by legal experts. a The questionnaire was not sent to Belarus or the Russian Federation and these countries are therefore not represented in this table, and no information was reported for: Armenia, Israel, Kazakhstan, Tajikistan, Turkmenistan, Uzbekistan. b Based on the most recent available country reporting from 2022 in the previous data collection round. c Although ‘non‐binary’ is now the internationally recognized term, ‘third gender’ is presented in this table to reflect the exact phrasing used in ECDC's 2024 HIV monitoring questionnaire, which was aligned with the available UNAIDS Global AIDS Monitoring indicator guidance. Number and names of countries with specific legal protections for trans people in Europe and Central Asia, end of 2023 (n = 47). a Note: Information provided by countries is self‐reported and may not have been verified by legal experts. The questionnaire was not sent to Belarus or the Russian Federation and these countries are therefore not represented in this table, and no information was reported for: Armenia, Israel, Kazakhstan, Tajikistan, Turkmenistan, Uzbekistan. Based on the most recent available country reporting from 2022 in the previous data collection round. Although ‘non‐binary’ is now the internationally recognized term, ‘third gender’ is presented in this table to reflect the exact phrasing used in ECDC's 2024 HIV monitoring questionnaire, which was aligned with the available UNAIDS Global AIDS Monitoring indicator guidance. Notably, six countries (Azerbaijan, Cyprus, Hungary, Latvia, Romania, San Marino) reported not criminalizing or prosecuting trans people but also explicitly reported lacking any specific legal protections in place for trans people. Two (4%) of 47 countries have punitive laws affecting lesbian, gay, bisexual, trans and intersex (LGBTI) people. Kyrgyzstan has laws against propaganda of non‐traditional sexual relations, while Poland's morality laws or religious norms limit LGBTI freedom of expression and association. Information for this indicator within Eastern European and Central Asian (EECA) countries is unknown due to the number of missing responses for this subregion (Table 1). National HIV policies Almost half of countries (23/50; 48%) involve trans people in the development of national policies, guidelines and strategies relating to their health (Table 2). Compared to other key populations, most countries involve men who have sex with men (38/50; 76%) and people who inject drugs (31/50; 62%), while the least cited population group was migrants (14/50; 28%). TABLE 2Status of national HIV prevention policy and programming related to trans people in European and Central Asian countries, a end of 2023.CountryNational policy, strategy and guidelinesNational prevention programmingParticipation b of trans people in health policy development (n = 50)Trans people mentioned in national HIV prevention strategy (n = 45)Trans people mentioned in national HIV testing strategy (n = 44)Provision of free (no cost) condoms/lubricant to trans people (n = 50)Individual cost of STI testing and treatment c for trans people (n = 46)AlbaniaFreeFree if insuredAndorraN/AN/AArmenia d AustriaFreeFree if insuredAzerbaijanFreeBelgiumFreeBosnia and HerzegovinaN/AFree if insuredBulgariaFree if insuredCroatia d FreeFree if insuredCyprusFreeFreeCzechiaFreeFree if insuredDenmarkFreeEstoniaFreeFreeFinlandFreeFranceFreeFreeGeorgiaFreeFreeGermanyN/AFree if insuredGreeceFree if insuredHungary d N/AIcelandN/AFreeIrelandN/AFreeFreeIsrael d FreeItalyFreeAvailable at a costKazakhstan d FreeFree if insuredKosovoKyrgyzstanFreeAvailable at a costLatviaFreeAvailable at a costLiechtensteinFree if insuredLithuaniaFree if insuredLuxembourgFreeFree if insuredMaltaFreeMoldovaFreeFreeMonacoFreeMontenegroN/AFree if insuredThe NetherlandsFreeNorth MacedoniaN/AN/AFreeFreeNorway d FreeFreePolandFree if insuredPortugalFreeFreeRomaniaFreeFreeSan MarinoN/AFreeSerbiaFreeFree if insuredSlovakiaFree if insuredSloveniaSpainFreeFreeSwedenFreeSwitzerlandAvailable at a costTajikistan d Free if insuredTürkiye d Free if insuredTurkmenistanUkraineFreeAvailable at a costUnited KingdomFreeFreeUzbekistan Total count of “yes” 23 27 19 23 23 e Note: Information on reported national HIV policy and programming for other key populations is presented in Data S1.Abbreviation: N/A, no national strategy in place. a The questionnaire was not sent to Belarus or the Russian Federation and these countries are therefore not represented in this table. b Participation is defined by UNAIDS as the active and meaningful involvement in the governance, planning, implementation and evaluation of national HIV strategies and services. c Response options for this indicator included: available free, free if the individual has insurance, available at a cost, not available. d Based on the most recent available country reporting from 2022 in the previous data collection round. e Total count of ‘provided for free’.YesNoMissing response Status of national HIV prevention policy and programming related to trans people in European and Central Asian countries, a end of 2023. Note: Information on reported national HIV policy and programming for other key populations is presented in Data S1. Abbreviation: N/A, no national strategy in place. The questionnaire was not sent to Belarus or the Russian Federation and these countries are therefore not represented in this table. Participation is defined by UNAIDS as the active and meaningful involvement in the governance, planning, implementation and evaluation of national HIV strategies and services. Response options for this indicator included: available free, free if the individual has insurance, available at a cost, not available. Based on the most recent available country reporting from 2022 in the previous data collection round. Total count of ‘provided for free’.YesNoMissing response YesNoMissing response Among 45 countries with a national prevention strategy to reduce new HIV infections, 27 (60%) included specific mention or focus on trans people. In contrast to other key populations within national HIV prevention strategies, most countries focused on men who have sex with men (41/45; 91%) and people who inject drugs and sex workers (39/45; 87% for both populations). Undocumented migrants were the least cited population within national prevention strategies (20/45; 44%). Among 44 countries with a national HIV testing strategy, 19 (43%) include specific reference to trans people, compared with 32 (73%) for men who have sex with men, 30 (68%) for people who inject drugs, 24 (55%) for migrants and 21 (48%) for former/current prisoners. Availability and cost of HIV and STI prevention programmes Approximately half of countries provide trans people with free access (no cost) to condoms and lubricant (23/50; 46%) and STI testing and treatment (23/46; 50%) (Table 2). STI testing and treatment services are otherwise only provided to trans people with insurance or at a cost to the individual in the remaining half of responding countries. In comparison, STI testing and treatment services are provided for free in around two‐thirds of countries for prisoners (32/50 countries; 64%), sex workers (29/50 countries; 58%) and men who have sex with men (27/50 countries; 54%). Avoidance of seeking healthcare services Specific study data reported in the HIV monitoring questionnaire by five countries (Germany, North Macedonia, Portugal, Spain, Ukraine) suggest that 44% (1244/2800) of trans people avoided seeking healthcare services in the previous 12 months. The highest proportion of healthcare‐seeking avoidance was found in North Macedonia (20/20; 100%) and Germany (1137/1770; 64%), while lowest in Ukraine (82/973; 8%). Given the heterogeneity of study methodologies across the five reporting countries, the findings on reasons for avoiding healthcare services could not be generalized. Continuum of HIV care Six countries provided data on the number of people diagnosed, treated and virally suppressed for trans‐feminine (Greece, Iceland, Kyrgyzstan, Luxembourg, the Netherlands, Sweden) and three for trans‐masculine (Greece, Kyrgyzstan, the Netherlands) people. The numbers diagnosed ranged from two to 286 (≤5 in three countries) trans‐feminine people and four to 15 trans‐masculine people. Given the small numbers and few countries with available data, it was not possible to compare country progress, nor calculate a reliable regional estimate of the CoC for trans people. DISCUSSION This was the first attempt to examine the wider HIV response for trans people in ECA, based on data reported through the 2024 ECDC Dublin Declaration monitoring questionnaire. Most responding countries could provide information related to national HIV policy and legal environments, while few had available data on the CoC for trans people. The lack of legal protections alongside punitive legislation reported by some EECA countries reflects existing civil society reporting on the regression and stagnation of laws and policies impacting the health and human rights of trans people in these subregions [12, 13]. Given that the HIV monitoring questionnaire was missing responses on the legal landscape for several EECA countries, the achievement of >10% of countries having punitive legislation against trans people may not be regionally representative. Key policies that can impact trans people's health, such as legal gender recognition (LGR) processes, were not examined as part of this analysis. Nevertheless, LGR is a human rights issue with documented positive effects on the mental and physical health of trans people, including reduced psychological distress and improved healthcare engagement [14]. According to the Trans Rights Map, LGR processes remain highly restrictive in many ECA countries, with mandatory sterilization, psychiatric diagnosis and bureaucratic delays creating additional hurdles [15]. Without accessible LGR, trans people frequently face systemic exclusion from healthcare services, as medical records often misalign with their gender identity; reinforcing pathologization and creating significant barriers to timely HIV‐related care [16]. Furthermore, robust LGR systems have important implications for public health monitoring, as they enable the generation of reliable data on trans populations that are essential for surveillance and evidence‐based policy. Compared to other key populations, trans people, along with migrants, were the least involved in developing national policies related to their health, and least referenced within national HIV prevention and testing strategies. This signals that many countries are failing to meet the UNAIDS recommendation to engage key populations in the development and implementation of national health policies, which is a crucial component to ensure meaningful and tailored HIV responses [8]. Among countries that actively involve trans people in the development of relevant health policies, most are situated within the EU/EEA region, whereas only six are in EECA countries. The lack of engagement for such policy development is particularly concerning as trans people, particularly trans people in EECA countries, appear to be the most exposed to instances of systemic, psychological and physical anti‐trans violence [17]. In approximately half of ECA countries, trans people lack access to free (no cost) provision of condoms and lubricant and must either pay out‐of‐pocket or be insured to access STI testing and treatment services. This highlights a critical access gap, given the broader societal stigma and discrimination faced by trans people contributes to reduced employment opportunities and income instability, social determinants that shape the contexts in which HIV acquisition occurs, including engagement in transactional sex [1, 3, 17]. While the limited reporting from five countries on the proportion of trans people avoiding seeking healthcare services in the previous 12 months may not represent the reality across the region, there is growing documentation on the degree to which trans and gender‐diverse populations in ECA experience stigma and discrimination in healthcare and community settings [17, 18, 19, 20]. An online survey by ECDC and the European AIDS Clinical Society on HIV stigma in healthcare settings found healthcare provider reluctance to care for trans people living with HIV linked to lack of relevant training, perception that trans people participate in immoral behaviour and concerns about increased risk of disease transmission [21]. The presence of these structural biases in healthcare provision creates unequal access and quality of care for trans people. Understood through the lens of Gender Minority Stress [22], such experiences of discrimination and stigma within healthcare settings are established drivers of healthcare avoidance among trans and other minoritized populations—a major public health concern with direct implications for HIV prevention, testing and treatment engagement. The incomplete and limited CoC data available on trans people in ECA countries demonstrates an urgent need to improve HIV surveillance and monitoring efforts, including collection of variables on trans populations at local and national levels. Enhanced collection of more robust data may inform the implementation and monitoring of tailored interventions to better describe and advance progress towards achieving viral suppression among all trans individuals living with HIV. Moreover, the CoC approach may not be fully appropriate to measure progress for trans people and other populations that are smaller in size, as the limited data available are not representative. To address the apparent national HIV surveillance and programme data gaps, alternative and more feasible approaches to data collection may be needed, such as community‐led monitoring [23] and/or development of standards to assess and benchmark the quality of care and services along the CoC for trans populations. Furthermore, challenges related to defining and collecting inclusive data on trans populations, that accurately reflect the diversity of gender identities, may be mitigated by applying a methodological framework grounded in international recommendations regarding the collection of Sexual Orientation and Gender Identity (SOGI) data [24]. Such frameworks standardize terminology, question design and response options to enable more consistent and representative data. LIMITATIONS The study has several limitations. Firstly, there is a strong reporting bias in which countries have responded to the questionnaire and the capacity to collect and report the available data. Additionally, while countries reported on the involvement of trans people in the development of national strategies, it remains unclear whether trans people were involved in responding to the country‐specific HIV monitoring questionnaire, or in the processes to collect relevant data and information. Given the limited data reported by a small number of countries, the dataset cannot be considered representative of the full WHO European region. CONCLUSION In the WHO European region, trans people are to a lesser extent than other key populations addressed in national HIV policies and strategies, and the data available from countries suggest lower levels of access to services, which may be linked to cost barriers, unsupportive legal environments and avoidance of seeking healthcare services. To address CoC data gaps and tailor HIV responses for trans people in the region, a deeper understanding of the contributing barriers and exploration of alternative approaches to data collection, beyond the existing CoC framework, is warranted. Without trans‐inclusive HIV prevention programmes, stigma‐free healthcare service provision and robust data collection, national and regional HIV responses may risk neglecting the specific and diverse needs among sub‐populations of trans people. AUTHOR CONTRIBUTIONS SN: Conceptualization; methodology; formal analysis; interpretation of results; writing – original draft preparation; reviewing and editing. PAC‐C: Conceptualization; writing – reviewing and editing. DR: Conceptualization; supervision; interpretation of results; writing – reviewing and editing. SB: Reviewing. ARS: Conceptualization; methodology; interpretation of results; writing – reviewing and editing. TN: Conceptualization; supervision; interpretation of results; writing – reviewing and editing. To enhance community relevance of this paper, ECDC invited PAC‐C of Trans Europe and Central Asia (TGEU) to be involved as a co‐author. FUNDING INFORMATION This manuscript was produced by the Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen, Denmark, under a framework contract with the European Centre for Disease Prevention and Control: ECDC/2023/029 “Monitoring progress towards the Sustainable Development Goals as they pertain to HIV, viral hepatitis, STls and TB in the EU/EEA and neighbouring countries”—RS/2024/DPR/26784/839. CONFLICT OF INTEREST STATEMENT PAC‐C is a member of the ViiV Healthcare Community Advisory Board and has provided consultancy and strategic input in relation to community engagement and HIV policy. PAC‐C also receives institutional funding from Gilead Sciences, Inc. in support of trans‐led HIV research and capacity building activities conducted through Trans Europe and Central Asia (TGEU). These relationships are unrelated to the current work. All other authors declare no conflicts of interest. Supporting information Table S1. 2024 ECDC HIV monitoring indicators related to trans populations. Data S1. Supporting Information.